Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

M1818

Sigma-Aldrich

Molindone hydrochloride

≥98% (HPLC), solid

Synonym(s):

3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-4H-indol-4-one hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C16H24N2O2 · HCl
CAS Number:
15622-65-8
Molecular Weight:
312.83
MDL number:
MFCD01718304
UNSPSC Code:
12352200
PubChem Substance ID:
24277995
Pricing and availability is not currently available.

Assay

≥98% (HPLC)

form

solid

color

off-white

solubility

H2O: 19 mg/mL

originator

Endo

SMILES string

CCC1=C(C)NC2=C1C(C(CN3CCOCC3)CC2)=O.Cl

InChI

1S/C16H24N2O2.ClH/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18;/h12,17H,3-10H2,1-2H3;1H

InChI key

GQWNECFJGBQMBO-UHFFFAOYSA-N

Gene Information

human ... DRD2(1813) , HTR2A(3356) , MAOA(4128) , MAOB(4129)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

D2 dopamine receptor antagonist; MAO inhibitor.

Features and Benefits

This compound was developed by Endo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301

Precautionary Statements

P301 + P310

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
014K4610V
014K4610

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The voices go, but the song remains the same: how can we rescue cognition in early-onset schizophrenia?
Peter Bachman et al.
Journal of the American Academy of Child and Adolescent Psychiatry, 51(5), 464-466 (2012-04-25)
Treatment of morbidly obese psychotic patients with molindone: three case reports.
Robert E McCue et al.
The Journal of clinical psychiatry, 70(11), 1606-1607 (2009-12-25)
R B Rosse et al.
Clinical neuropharmacology, 19(5), 444-450 (1996-10-01)
This preliminary investigation examined the therapeutic efficacy of two doses of oral D-cycloserine (5 and 15 mg p.o. b.i.d.) administered as an adjuvant to molindone (150 mg p.o. q.d.) in the treatment of schizophrenia. D-Cycloserine is an agonist at the
Jon McClellan et al.
Journal of the American Academy of Child and Adolescent Psychiatry, 46(8), 969-978 (2007-08-02)
The Treatment of Early Onset Schizophrenia Spectrum Disorders Study is a publicly funded clinical trial designed to compare the therapeutic benefits, safety, and tolerability of risperidone, olanzapine, and molindone in youths with early-onset schizophrenia spectrum disorders. The rationale, design, and
M Froimowitz et al.
Drug design and discovery, 15(2), 63-81 (1997-08-01)
This study is an attempt to incorporate the butyrophenones, an important class of nontricyclic antipsychotic drugs, into a previously proposed pharmacophore model of tricyclic dopamine D2 receptor antagonist ligands. Conformational energy calculations were performed using the MM3-92 program on spiperone
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service